AU2116201A - A therapeutic mixture of hmg-coa reductase inhibitors - Google Patents
A therapeutic mixture of hmg-coa reductase inhibitorsInfo
- Publication number
- AU2116201A AU2116201A AU21162/01A AU2116201A AU2116201A AU 2116201 A AU2116201 A AU 2116201A AU 21162/01 A AU21162/01 A AU 21162/01A AU 2116201 A AU2116201 A AU 2116201A AU 2116201 A AU2116201 A AU 2116201A
- Authority
- AU
- Australia
- Prior art keywords
- hmg
- coa reductase
- reductase inhibitors
- therapeutic mixture
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42081699A | 1999-10-19 | 1999-10-19 | |
US09420816 | 1999-10-19 | ||
PCT/US2000/041304 WO2001028499A2 (en) | 1999-10-19 | 2000-10-19 | A therapeutic mixture of hmg-coa reductase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2116201A true AU2116201A (en) | 2001-04-30 |
Family
ID=23667961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU21162/01A Abandoned AU2116201A (en) | 1999-10-19 | 2000-10-19 | A therapeutic mixture of hmg-coa reductase inhibitors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1225885A4 (en) |
AU (1) | AU2116201A (en) |
CA (1) | CA2388530A1 (en) |
MX (1) | MXPA02004021A (en) |
WO (1) | WO2001028499A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6425881B1 (en) * | 1994-10-05 | 2002-07-30 | Nitrosystems, Inc. | Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
WO2000056328A1 (en) | 1999-03-19 | 2000-09-28 | Enos Pharmaceuticals, Inc. | Increasing cerebral bioavailability of drugs |
USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
US20060205727A1 (en) * | 2005-03-11 | 2006-09-14 | Wayne Kaesemeyer | Combination therapy for endothelial dysfunction, angina and diabetes |
CN105246472B (en) * | 2013-03-15 | 2018-10-12 | 武汉朗来科技发展有限公司 | Composition containing ornithine and/or L-aminobutanedioic acid and its application |
WO2014139469A1 (en) * | 2013-03-15 | 2014-09-18 | Wuhan Qr Science And Technology Development Co. | Ornithine- or aspartate-containing compositions and the uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
US5968983A (en) * | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
-
2000
- 2000-10-19 AU AU21162/01A patent/AU2116201A/en not_active Abandoned
- 2000-10-19 MX MXPA02004021A patent/MXPA02004021A/en unknown
- 2000-10-19 CA CA002388530A patent/CA2388530A1/en not_active Abandoned
- 2000-10-19 EP EP00984562A patent/EP1225885A4/en not_active Withdrawn
- 2000-10-19 WO PCT/US2000/041304 patent/WO2001028499A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1225885A4 (en) | 2004-04-21 |
CA2388530A1 (en) | 2001-04-26 |
EP1225885A2 (en) | 2002-07-31 |
WO2001028499A2 (en) | 2001-04-26 |
MXPA02004021A (en) | 2004-08-23 |
WO2001028499A3 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104258A3 (en) | Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor | |
AU6762400A (en) | Inhibitors of factor xa | |
AU5283800A (en) | Inhibitors of factor xa | |
AU5158100A (en) | Inhibitors of factor xa | |
AU5155500A (en) | Inhibitors of factor xa | |
AU6580000A (en) | Pharmaceutical compositions comprising a hmg reductase inhibitor | |
AU3857300A (en) | Inhibitors of factor xa | |
AU6111000A (en) | Inhibitors of viral helcase | |
IL154977A0 (en) | Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent | |
AU5283600A (en) | Inhibitors of factor xa | |
AU3368400A (en) | Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammationassociated with pulmonary disease | |
AU2002310798A1 (en) | Pharmaceutical compositions comprising a hmg-coa reductase inhibitor | |
AU2003270154A1 (en) | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor | |
AU7761398A (en) | Hmg-coa reductase inhibitor preparation process | |
AU4543699A (en) | Multibinding inhibitors of hmg-coa reductase | |
AU2002306734A1 (en) | Inhibitors of plasmepsins | |
AU2116201A (en) | A therapeutic mixture of hmg-coa reductase inhibitors | |
AU5587200A (en) | Synthesis of substituted amidines | |
AU2252101A (en) | New synthesis of SPLA2 inhibitors | |
GB2371748B (en) | HMG-COA reductase inhibitor extended release formulation | |
AU2050001A (en) | Synthesis of indole-containing spla2 inhibitors | |
AU8005100A (en) | Inhibitors of neuraminidases | |
AU2177701A (en) | Use of hmg-coa reductase inhibitors for treating seborrhea | |
AU4021700A (en) | Methods of use of beta1-integrin inhibitors | |
AU2002305868A1 (en) | Inhibitors of reggamma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |